Clinical Research is an integral part of oncology at Bon Secours Richmond Health System. Clinical trials give patients access to the newest and best treatments for cancer. Bon Secours Richmond Health System is proud to provide the same options as leading national cancer centers. Whether it is looking at new surgical or radiation interventions, or giving a brand new medication, We are striving to find better ways to treat, prevent, and manage cancer.
To inquire about participation in a clinical trial, please contact us at (804) 893-8717.
Please see the available, in-progress clinical trials at Bon Secours Richmond Health System. You may filter these results by searching by disease type or keyword.
Search Clinical Trials
SAR408701 versus docetaxel in previously treated, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)-positive, metastatic nonsquamous non–small-cell lung cancer patients (CARMEN-LC03)
What are clinical trials, and why are they important? Are there different types of cancer clinical trials? Who manages clinical …
A Phase II Trial of Sacituzumab Govitecan (TRODELVY™) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases …
Alliance Protocol A212102, “Blinded Reference Set for Multicancer Early Detection Blood Tests” https://www.clinicaltrials.gov/ct2/show/NCT05334069?term=NCT05334069&draw=2&rank=1
A Study of imlunestrant vs physician’s choice endocrine therapy as adjuvant treatment after 2 to 5 years of standard adjuvant …
Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate …
COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)
A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma
Phase III IGRT and SBRT vs IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate Cancer